Tivicay
NDC Package 67296-1818-3

11-digit billing NDC: 67296181803

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Tivicay is ‑ TIVICAY and TIVICAY PD are indicated in combination with: other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV‑ 1) infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve)aged at least 4 weeks and weighing at least 3 kg [ see Microbiology (12.4)]. Marketed by Redpharm Drug, Inc., this product is identified by NDC 67296-1818 and is authorized under FDA application NDA204790.

Identification & Billing

NDC Package Code
67296-1818-3
Package Description
3 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
67296181803
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tivicay
Dosage Form
-
Usage Information
‑ TIVICAY and TIVICAY PD are indicated in combination with: other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV‑ 1) infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve)aged at least 4 weeks and weighing at least 3 kg [ see Microbiology (12.4)]. TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.

Regulatory & Marketing

Labeler Name
Redpharm Drug, Inc.
FDA Application #
NDA204790
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-13-2013
Listing Expiration
12-31-2025
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (67296-1818). Click a package code to view its specific billing and regulatory data.

5 TABLET, FILM COATED in 1 BOTTLE
28 TABLET, FILM COATED in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67296-1818-3 identifies a specific commercial package of 3 tablet, film coated in 1 bottle of Tivicay, labeled by Redpharm Drug, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Redpharm Drug, Inc. on August 13, 2013. The current certification is valid through December 31, 2025.

How is this Redpharm Drug, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67296181803. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
67296-1818-3
11-Digit CMS (5-4-2)
67296-1818-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.